{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Solomon SD"],"funding":["Intramural NIH HHS"],"pagination":["2104-13"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC2965408"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["117(16)"],"pubmed_abstract":["<h4>Background</h4>Observational studies and randomized trials have reported increased cardiovascular risk associated with cyclooxygenase-2 inhibitors. Prior placebo-controlled randomized studies had limited ability to assess the relationship of either celecoxib dose or pretreatment cardiovascular status to risk associated with celecoxib. Our aim was to assess the cardiovascular risk associated with celecoxib in 3 dose regimens and to assess the relationship between baseline cardiovascular risk and effect of celecoxib on cardiovascular events.<h4>Methods and results</h4>We performed a patient-level pooled analysis of adjudicated data from 7950 patients in 6 placebo-controlled trials comparing celecoxib with placebo for conditions other than arthritis with a planned follow-up of at least 3 "],"journal":["Circulation"],"pubmed_title":["Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis."],"pmcid":["PMC2965408"],"funding_grant_id":["Z99 EY999999"],"pubmed_authors":["Goss PE","Finn PV","Pater JL","Chew EY","Obara S","Fowler R","Levin B","Cross Trial Safety Assessment Group","Meinert CL","Kim J","Martin B","Arndt G","Viner J","Wittes J","Lance P","Bertagnolli MM","Solomon SD","Hawk E","Arber N"],"additional_accession":[]},"is_claimable":false,"name":"Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.","description":"<h4>Background</h4>Observational studies and randomized trials have reported increased cardiovascular risk associated with cyclooxygenase-2 inhibitors. Prior placebo-controlled randomized studies had limited ability to assess the relationship of either celecoxib dose or pretreatment cardiovascular status to risk associated with celecoxib. Our aim was to assess the cardiovascular risk associated with celecoxib in 3 dose regimens and to assess the relationship between baseline cardiovascular risk and effect of celecoxib on cardiovascular events.<h4>Methods and results</h4>We performed a patient-level pooled analysis of adjudicated data from 7950 patients in 6 placebo-controlled trials comparing celecoxib with placebo for conditions other than arthritis with a planned follow-up of at least 3 ","dates":{"release":"2008-01-01T00:00:00Z","publication":"2008 Apr","modification":"2025-04-18T21:27:32.026Z","creation":"2019-03-26T23:49:32Z"},"accession":"S-EPMC2965408","cross_references":{"pubmed":["18378608"],"doi":["10.1161/circulationaha.108.764530","10.1161/CIRCULATIONAHA.108.764530"]}}